Revolution Medicines (RVMD) recently dosed the first patient in its initial human trial of RMC-5127, a RAS(ON) G12V selective inhibitor, putting fresh attention on how investors assess this clinical-stage oncology stock.

The dosing news arrives after a volatile few months for the stock, with a recent 1-day share price return of 1.39% and a 90-day share price return of 59.79%. The 1-year total shareholder return of 131.07% and 3-year total shareholder return of almost 3x indicate that momentum has been building over time.

If this RAS-focused progress has caught your attention, it could be a good moment to see what else is happening in oncology and biotech through our screen of 25 healthcare AI stocks.

With Revolution Medicines now trading at US$97.49 after a strong 1 year and 3 year run, investors have to ask whether current enthusiasm around its RAS pipeline leaves the stock undervalued or if the market is already pricing in future growth.

Preferred Price-to-Book Multiple of 11.6x: Is it justified?

Revolution Medicines is currently trading on a P/B of 11.6x at a last close of $97.49, with mixed signals when you line that up against peers and simple valuation models.

The P/B multiple compares the company’s market value to its net assets on the balance sheet, which can be a common reference point for early stage or unprofitable biotechs where earnings and revenue are not yet meaningful. At 11.6x, investors are effectively paying more than eleven times the company’s book value per share, which reflects how much of the thesis rests on future RAS(ON) pipeline progress rather than current cash generation.

On one side, RVMD is described as good value when you compare its 11.6x P/B to a peer average of 15.5x, which suggests the market is assigning a lower premium than some similar names. On the other side, that same 11.6x multiple is described as expensive against the broader US biotechs industry average of 2.6x. This is a much lower bar and highlights how much optimism is embedded compared to the sector overall.

With our DCF work, the SWS DCF model estimates a future cash flow value of $477.98 per share versus the recent price around $97. This implies the share price is trading at roughly 20% of that modelled value. The model works by projecting potential future cash flows and then discounting them back to today using an appropriate rate, which can be useful for a company like Revolution Medicines that currently reports a loss of $960.978m and no revenue.

Given RVMD is a clinical stage precision oncology company with forecast revenue growth of 60.1% per year and expectations that it remains unprofitable over the next 3 years, most of the weight in both the P/B multiple and the DCF model sits on what the pipeline might deliver rather than any current earnings base.

Result: Price-to-book of 11.6x (ABOUT RIGHT)

However, the story could change quickly if key RAS(ON) trials disappoint or if ongoing losses near $961m begin to pressure funding options and timelines.

Another View: DCF Points to a Very Different Price

While the 11.6x P/B suggests RVMD is roughly in line with what you might expect for a high conviction biotech, our DCF model tells a very different story. The SWS DCF model indicates a future cash flow value of $477.98 per share versus the recent price around $97, which implies a very large gap investors need to interpret carefully.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Revolution Medicines for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 53 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Revolution Medicines Narrative

If you see the data differently or prefer to piece things together yourself, you can build a personalised view of RVMD in just a few minutes, starting with Do it your way.

A great starting point for your Revolution Medicines research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If RVMD has sharpened your focus, do not stop here. Broaden your watchlist with a few targeted idea lists that match different investing priorities.

• Target potential value opportunities by scanning our collection of 53 high quality undervalued stocks built from companies with supportive fundamentals and pricing that may warrant a closer look.
• Prioritise resilience by reviewing our 86 resilient stocks with low risk scores so you can focus on businesses that score well on financial and risk checks.
• Hunt for earlier stage potential by checking our 25 elite penny stocks with strong financials where we flag smaller companies that still meet basic quality filters.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.